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Abstract 
Recurrent aphthous stomatitis is one of the most common oral mucosal diseases seen by dental 
professionals, and yet its etiology remains unclear, and its management based on less than 
robust evidence. The literature remains confused because of the lack of clarity in diagnosis and 
the lack of a standardized ulcer severity scoring system and agreed outcome measures. 
However, recent literature is encouraging in meeting these aims. There is agreement that RAS 
is a localized mucosal disease not secondary to systemic disease and therefore distinguishable 
from over forty other types of oral ulcers. Disease severity scores have been introduced and 
outcome measures have become more standardized. RAS appears to be an auto-immune 
disease directed at epitopes of heat shock proteins while most recent work on etiology has 
focused on cytokines and genetics. Pro-inflammatory cytokines including TNFa and IL-6 and 
IL-17 are raised in RAS and TNF inhibitors can inhibit episodes of ulceration. Many local 
anti-inflammatory agents will help ulcers heal, and local steroids remain the treatment of 
choice. Some systemic drugs have evidence based data indicating efficacy at preventing new 
ulcers including colchicine, prednisolone, thalidomide, pentoxyfilline and dapsone. The field 
would benefit from further trials combining local and systemic therapy using defined outcome 
measures.    
 
Keywords : recurrent aphthous stomatitis, oral ulceration, interleukins, steroids, colchicine, 
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2 
 
Introduction 
Diagnosis 
The correct diagnosis of Recurrent Aphthous Stomatitis (RAS, sometimes also referred to as 
recurrent oral ulceration or canker sores) is central to oral medicine. There are over forty types 
of mouth ulcers, many related to systemic diseases, but RAS is characterized by oral ulcers, 
occurring singly or in crops that usually last for 7 to 21 days before healing spontaneously. 
These ulcers recur after a variable period, which may be a few days or several weeks. RAS can 
be separated clinically into three types: minor aphthous ulcers (MiAU), major aphthous ulcers 
(MjAU) and herpetiform ulcers (HU) (see Table I). There has been a tendency for clinicians to 
describe any ulcer occurring in the mouth as aphthous. However, aphthous ulcers have been 
carefully defined to allow differentiation from the many other types of recurrent ulcers 
occurring in the oral cavity and are not associated with systemic abnormalities [1].  
Recurrent oral ulceration 
 Recurrent aphthous stomatitis 
  Minor 
     Major 
        Herpetiform 
  Recurrent aphthous ulcers with Behçet’s disease 
  Smoking-related aphthous ulcers 
  Recurrent erythema multiforme  
    Atypical recurrent oral ulceration 
Persistent oral ulceration 
 Secondary to hematological deficiency state/anemia 
 Secondary to a gastrointestinal enteropathy 
 Secondary to a dermatological condition 
 Secondary to connective tissue disease 
Table 1: Differential types of recurrent oral ulceration and major groups of persistent oral 
ulceration (modified from [1]) 
Prevalence of RAS 
Wild overestimates of the prevalence abound, but if RAS is defined as more than two spontaneously 
occurring episodes per year, then an average prevalence in the population of around 10% appears 
reasonable. Many studies struggle with definitions and ask whether subjects ever get mouth ulcers. It 
is likely that such studies give a prevalence much greater than those adhering to the RAS definition.  
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Reported estimates vary between 1.5% and 28% in different parts of the world, suggesting that there 
may be genetic differences to account for these geographic variances [2-4]. The prevalence in 
children may be greater than adults [5, 6]  
 
Aetiology 
An impressive array of factors has been implicated in the etiology of RAS, although it is 
likely that many of them influence the nature of the disease rather than cause it. These include 
hereditary factors, hypersensitivity predisposition, socioeconomic status, psychological 
factors, endocrine factors, microbial agents, and chemical factors in foods. There is no 
evidence that food allergy is causative in RAS, although it is likely that food allergy can 
initiate some cases of oral ulceration which might in the unwary appear to mimic RAS. 
Hematological deficiencies may cause some types of oral ulceration but may also influence 
susceptibility to other types of ulceration. In addition, lesions clinically consistent with RAS 
are found in association with some systemic or multisystem illnesses such as Behçet's 
syndrome, clinical neutropenia, vitamin B12 deficiency, and celiac disease. RAS is thus best 
defined as being recurrent oral ulceration in the absence of known systemic factors (table 1). 
 
Some studies have reported an association between RAS and a variety of psychological 
factors including anxiety, stress and depression [7-10], but salivary cortisol levels are often 
normal in RAS patients even during the active phase [11]. Nevertheless, the concept of 
initiation of RAS through expression of heat shock (stress) proteins (HSP) such as during 
viral illnesses and RAS reoccurrences when patients under stress with possible re-expression 
of HSP does relate well to the evidence of reactivity of RAS patients to epitopes of HSPs (see 
below). 
Genetic Aspects 
A family history of ulcers is found in approximately 40% of patients, and the highest 
incidence is found in siblings of parents both of whom have RAS. Identical twins show a 90% 
concordance, implicating a genetic component [12]. The prevalence of human leukocyte 
antigens HLA-A2 and B12 (B44 subtype) was higher in RAS patients than in controls, 
suggesting that major histocompatibility complex (MHC) class1 gene products may be 
associated [13], but it is likely that genes other than those associated with HLA may be more 
closely linked. Genome wide association studies (GWAS) have not yet borne fruit, possibly 
because of the heterogeneity of RAS and sometimes inconsistency in diagnosis.  
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A number of recent studies have examined polymorphisms of individual genes in factors 
thought to be associated with the pathogenesis of RAS. Single nucleotide polymorphisms 
(SNPs) of IL-10 gene (C/A-1082, C/T-819 and C/A-592) were significantly higher in RAS 
patients [14]. Polymorphisms of IL-1beta and TNF-alpha production were associated with an 
increased risk of RAS development [15]. Genotypes of IL-6 gene -572G>C and -174G>C 
polymorphisms were found to be significantly higher in 184 Turkish RAS subjects [16]. 
Matrix Metalloproteinase (MMP-9) polymorphisms have been described in RAS patients 
[17] and a mutation of Methylene tetrahydrofolate reductase (MTHFR) gene C677T related 
slightly curiously with the number of oral ulcers in RAS patients [18].  
These findings taken together suggest that gene abnormalities may be associated with 
susceptibility to RAS and that it is likely that susceptibility is related to a number of 
abnormalities. The relevance of such studies would be greatly enhanced if there was further 
understanding of the actual mechanisms and pathways leading to RAS!.  
 
Immunopathogenesis:  
The exact pathogenesis of RAS, a common mucosal disorder is still unknown. A role for 
autoimmunity in RAS was first suggested in the 1960s [19]. Although no definitive infective 
microorganism has been identified, a currently accepted hypothesis is that patients are 
exposed to an unidentified infective or other agent, which, in susceptible patients, triggers 
release from normal suppression of an autoimmune response against oral mucosa. The agent 
is thus either in, or cross-reacts with, oral mucosa in these patients. Autoantibodies, cytotoxic 
lymphocytes, and circulating lymphocytes sensitized to oral mucosa have been demonstrated 
in RAS patients.  In most RAS patients anti-epithelial antibodies, which are cytotoxic to oral 
epithelial cells, can be found [20]. 
A potential cross-reacting agent is heat shock protein (hsp). Hasan et al. [21] showed that T 
lymphocytes from patients with RAS recognized a unique peptide sequence of the 
mycobacterial hsp 65 antigen. Responses to a human 60-kDa hsp peptide 116-130 were also 
raised. This finding suggests that RAS might be initiated by the microbial hsp peptide, which 
stimulates the mucosal Langerhans cells to generate autoreactive T-cell clones primed to the 
homologous peptide. The specific peptide epitope 91-105 of the 65-kDa mycobacterial Hsp 
against which RAS patients react has been identified [22]. This concept that Hsp peptides 
contribute to RAS pathogenesis is strengthened by the demonstration that patients with 
Behcets syndrome react to a different peptide, and that in animal models, immunization with 
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this peptide leads to a form of Behcets syndrome [23] which can be blocked by inducing oral 
tolerance in models or in patients with Behcets [23]. 
 
Others have suggested that TLR2 (Toll-like receptor) stimulating peripheral blood 
mononuclear cells could be involved in the pathogenesis of RAS [24]. TLRs are a group of 
membrane receptors which can recognise molecules derived from bacteria, viruses and fungi 
that are involved in both immune regulation and control of epithelial barrier integrity. The 
hypothesis suggests that RAS occurs due to an imbalance of Th1/Th2 immune response as 
well as epithelial barrier dysfunction of the oral mucosa caused by impairment of TLR2 
pathways, which permitted the contact of immune competent cells from the lamina propria 
with oral antigens that are rich in Th1 cytokines and that will influence the onset of RAS [24, 
25]  
 
RAS is characterised histopathologically by a marked inflammatory infiltrate that initially 
consists predominantly of lymphocytes which then becomes mixed with neutrophils as the 
lesion develops [26] and adjacent keratinocytes become HLA-DR (an MHC class II cell 
surface receptor) and ICAM-1 (Intercellular Adhesion Molecule-1) positive [27,28]. 
Activated endothelial cells expressing adhesion molecules including intercellular adhesion 
molecule-1 (ICAM-1), vascular adhesion molecule-1 (VCAM-1) and E-selectin could 
become the target for the cytotoxic damage. The early expression of ICAM-1 by 
keratinocytes could be important in the early recruitment of lymphocytes. This interaction 
between keratinocytes and CD8+ cytotoxic T cells binding with ICAM-1 of keratinocytes 
could be responsible for the epithelium destruction and ulcer formation at the site [28]. The 
predominance of CD8+ cytotoxic T cells in the ulcerative stage has been demonstrated [27, 
28].  
 
The role of Oral Flora 
These theories of pathogenesis suggest that the oral flora and the host-pathogen interface are 
important components in the aetiology of RAS and have stimulated new study of both. Early 
studies had suggested that L-forms of bacteria (those without a cell wall), mycoplasma, 
lactobacilli or species of streptococci might be carrying the offending cross reacting antigen.  
Using DNA analysis, the microbiota of the non-inflamed buccal mucosa in RAS appears to 
differ between patients and controls, especially if lesions were present. This suggested that a 
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disturbance in the normal buccal microbiota triggers the presence of lesions or that presence 
of lesions alters the microbiota [29, 30]. Using high-throughput 16S rRNA gene sequencing, 
mucosal microbiome changes in mucosae of patients with RAS were demonstrated, including 
increased Bacteroidales species [31]. Several studies have suggested the possible 
involvement of Helicobacter pylori infection in individuals with RAS, but the relationship 
remains controversial. A recent meta-analysis by Li et al [32] supports the weak association 
between RAS and H. pylori infection (30% in RAS versus 20% in controls) and suggests that 
in a minority of patients H pylori eradication might be of clinical benefit. 
Analysing current oral flora in patients who have a history of RAS seems unlikely to 
determine a triggering role of a specific microbial species, but may shed light on 
perturbations associated with RAS. 
 
Role of cytokines in RAS 
Cytokines are crucial mediators of immune reactivity and have been a major focus in the 
immunopathogenesis of RAS. Current evidence suggests that RAS may result from an 
abnormal cytokine cascade in the oral mucosa that leads to a cell-mediated immune response 
directed towards focal area of the oral mucosa [33]. There are two types of cytokines: Pro-
inflammatory cytokines that induces cell-mediated immunity and produced by Th1 (IL-2, IL-
12, IFN-g and TNF-a) and anti-inflammatory cytokines (IL-4, IL-5, IL-10 and IL-13) 
produced by Th2 and promote humoral immunity and suppression of cell-mediated 
immunity. The imbalance of Th1/Th2 immune response is strongly influenced by their 
cytokine environment [33,34]. The predominance of pro-inflammatory cytokines (IL-2, IL-12 
TNF-a, and IFN-g) in lesional biopsies of RAS patients were demonstrated in several studies 
[35, 33]. Type 1 pro-inflammatory cytokines like interleukin-2 (IL-2), interleukin-12 (IL-12), 
interferon-gamma (IFN-g) and tumour necrosis factor-alpha (TNF-a) have been suggested to 
be implicated in the aetiopathogenesis of RAS [34] 
 
Tumour necrosis factor-alpha (TNF-a) is an important inflammatory mediator and critical 
cytokine for adequate host defences and because it can have direct toxic effects on epithelial 
cells is a clear candidate for damage in RAS as well as protection in general. TNF-a is 
thought to play a major role in the activation of the inflammatory process in RAS by its effect 
on endothelial cells adhesion molecules and its chemotactic effect on neutrophils [36].  A 
direct role for TNFa in RAS is suggested by the efficacy of medications which inhibit TNF 
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including thalidomide and pentoxifylline [37, 38] and infliximab [39]. Serum TNF, 
presumably reflecting local production, has been reported as raised in a third of patients with 
RAS, and related both to disease severity and stage of RAS [40] but findings were not confirmed in 
all studies [37]. However, salivary TNF-a levels were reported as raised in both ulcerative 
and remission stages of RAS [41], and in the ulcer phase [42]. 
  
IL-6 is a multifunctional pro-inflammatory cytokine produced by macrophages, lymphocytes, 
keratinocytes, fibroblasts and endothelial cells in response to a variety of external stimuli. 
Raised serum concentrations of IL-6 and IL-8 were found in 25% and 60% of RAS 
respectively and in both major and minor types [43, 44, 45] suggesting that serum IL-8 may 
be a more sensitive marker than IL-6 in monitoring disease activity of RAS. Other studies 
have not found significant differences in levels of IL-6 in serum [46] or in saliva [41]. 
 
IL-8 is a chemokine produced by keratinocytes, macrophages, mast cells and endothelial 
cells. It is known as neutrophil chemotactic factor. Keratinocytes in the pre-ulcerative stage 
of RAS may produce a significant level of IL-8 which in turn activate neutrophils and attract 
cytotoxic T cells. Sun et al [44] found that serum concentrations of IL-8 were raised in RAS 
patients and significantly increased levels of serum IL-8 are found in Behcet's disease 
patients associated with recurrent oral ulcers [46, 47].  
 
Recently a newer subset of Th17 lymphocytes producing IL-17 were described in relation to 
mucosal diseases. The main function of Th17 cells is thought to be their ability to recruit 
neutrophils and increase the production of cytokines and chemokines by epithelial cells. 
Serum levels of IFN-g and IL-17 were significantly increased in RAS patients [48]. Human 
oral keratinocytes can produce IL-17 and stimulate the production of IL-8 and TNF-a in RAS 
patients compared with healthy controls [49].  
Overall, there seems to be sufficient evidence to suggest that pro-inflammatory cytokines 
may be associated with RAS activity. 
 
Assessing Ulcer Severity 
The need for a standardised method for assessing ulcer severity and its use in determining 
treatment responses has long been recognised. However, authors have used such a variety of 
outcome measures that a Cochrane review of RAS treatment was not possible [50]. However, 
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recently Tappuni et al [51] have reported an ulcer severity scoring system which converts 
RAS characteristics of number of ulcers, size, duration, length of ulcer free period, site 
affected and pain score into numerical values out of 10 and combined to give a total out of 
60. Its use has been demonstrated in a study on the efficacy of betnesol mouthwashes and 
systemic colchicine in RAS treatment [51]. This Ulcer Severity Score (USS) scoring system 
aided in monitoring the progress of the condition, helped in assessing the efficacy of any 
treatment and in the management of the ulcers as well as being easy to use. An example of 
sequential scores in major RAS patients using Colchicine is shown (see figure) 
 
Studies measuring the effect of RAS on quality of life have been reported [52]. The Oral 
Health Related Quality of Life (OHR-QoL) score of RAS patients provided an additional 
dimension which may help to improve the impact of RAS on an individual's life. Oral Health 
Impact Profile (OHIP-14) measured the degree of RAS impact on functional limitation, pain, 
psychological discomfort, physical disability, psychological disability, social disability and 
handicap. Improvement after treatment with colchicine was found and thus provides a patient 
based assessment of the effectiveness of treatment [52]. 
 
 
Figure. Ulcer severity scores of individual Major RAS patients (n=10) who were treated with 
colchicine 0.5mg/day for 12 months and then 1mg/day for 6 months. USS = Ulcer severity 
score [51]. Arrows indicate times of drug administration. (modified from Alsahaf S [92]) 
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Management of RAS 
There are no internationally accepted guidelines for RAS treatment despite RAS being one of 
the most common oral disorders. Apart from the relief of pain, there are two main therapeutic 
approaches a) to help heal current ulcers and b) to prevent new episodes of ulceration. Many 
topical preparations attempt to help the healing process and many have claimed efficacy, 
whilst prevention of new occurrences usually requires systemic medications. 
Topical therapies 
Steroid tablets used as a mouthwash are one of the most common treatments used in 
specialised clinics. It is a recognised therapy for RAS and generally accepted as effective in 
controlling this common oral condition [53], despite the limited clinical evidence to support 
its efficacy.  
Betnesol mouthwash is a Betamethasone sodium phosphate tablet 500mcg dissolved in 10 
ml of water and used as a mouthwash for 3 minutes then discarded. It is administered four 
times a day (QID) in the presence of ulcers and twice a day (BID) in between ulcer attacks 
[1] A three-month study by Tappuni et al [51] compared Betnesol mouthwash (four times a 
day) with Betnesol mouthwash and Colchicine tablets 0.5mg a day. Using an ulcer severity 
scoring (USS) system, the authors showed significant improvement in USS of most patients 
in the Betnesol group, as well as in the combined treatment of Colchicine plus Betnesol. 
A wide range of topical therapies have been used in the treatment of RAS but there 
are very few published randomised clinical trials to support their efficacy. Not all are 
available worldwide. Dexamethasone ointment applied 3 times a day for 5 days can reduce 
ulcer size and pain alongside an improvement in healing time [54]. Dexamucobase was at 
least as effective as triamcinolone acetonide in Orabase in improving healing time [55]. 
Amlexonax is an anti-inflammatory, anti-allergic and immunomodulatory (not currently 
available in the USA). Two reasonably sized double blind trials (100-200 RAS patients) 
showed that Amlexonax oral adhesive tablets applied 4 times a day for 5 days were effective 
at promoting healing and reducing pain [56, 57]  
Topical Tetracycline mouthwash has been used alone or in combination with liquid anti-
fungals or topical steroids, especially in the treatment of Herpetiform RAS and remains the 
treatment of choice in this type of RAS which appears largely resistant to steroids [58]. In 
major and minor RAS, topical Tetracycline or Minocycline mouthwashes as a local anti-
bacterial can be expected to reduce the severity of the ulcerations and pain but not prevent 
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recurrences [59, 60]. Similar effectiveness in promoting healing and reducing pain has been 
reported with Penicillin G mouthwashes [61]. 
Several topical herbal treatments have shown efficacy as alternative therapies including 
Aloe Vera gel [62], Berberine gelatine [63]. Yunnan baiyao [64], Myrtus communis [65] and 
Citrus oil with magnesium salts [66]. All of these topical herbal therapies have been used for 
the treatment of Minor RAS only.  Lalla et al [67] demonstrated in a randomised, placebo-
controlled, double-masked, parallel-arm, clinical trial that daily multivitamin supplements did not 
improve the number or duration of RAS episodes in 160 subjects.  
 
Systemic Therapies: 
The main goals of systemic therapies are to reduce the frequency of recurrences and to 
minimise the duration of ulcers. Systemic immunomodulatory medications have therefore 
been tried for the treatment and management of severe and constantly recurring RAS, 
including systemic Prednisolone [68], Dapsone [69], Levamisole [70], Azathioprine [71], 
Pentoxifylline [37], Colchicine [73, 51] and Thalidomide [38] (see table 2).  These may 
produce remission or reduction in symptoms but all have side effects. Therefore the treatment 
choices should be guided by the balance between the severity of the RAS and the potential 
adverse effect of medications. 
Table 2: Examples of Systemic treatment of RAS 
TREATMENT RESULTS COMMENTS AUTHORS 
Levamisole 
50mg/tds 
 
Reduction in ulcers in up to 
66% 
Levamisole alone  
effective mode of 
therapy  
40,47, 70, 71,86, 89 
90 
Infliximab 
Adalimumab 
Golimumab 
Complete remission 
 In up to 89% 
Long term expensive 
25% side effects 
88, 
Dapsone 50-125mg Improvement in 60% Gastric side effects in 
25% 
69, 78 
Colchicine 
500ugm/day 
Effective in over 70% Gastric side effects at 
higher doses 
72, 78, 79, 80, 81, 
82 
Prednisolone 
25mg/day 
Pain, Ulcer number and 
duration reduced 
2 months  
Not for long term 
68, 71, 87 
Azathioprine 
25mg/day 
Reduction of RAS in 
Behcets (see table 1) 
Effective in Behcets. 
Perform TPMT assay 
73, 74 
Thalidomide 
50mg/day 
Complete remission 
 in 85%. Beware 
 side effects of neuropathy 
3 months minimum 38, 76, 77 
Tetracycline 
Mouthwash four 
times daily 
 Remission in majority but 
not all 
  
Herpetiform RAS 
 
58, 59, 60 
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Pentoxifylline 
400mg/tds 
Ulcer pain, size, number 
reduced.  
ulcer free period increased 
2 months minimum  
 
37, 
TPMT= Thiopurine methyltransferase 
 
Azathioprine is an immunosuppressive drug which belongs to the chemical class of purine 
analogues and is used in treatment of autoimmune diseases. 1 in 500 patients have a genetic 
deficiency of the enzyme Thiopurine Methyltransferase (TPMT) which metabolises 
azathioprine so assay is mandatory. There are very few published studies using Azathioprine 
for the management of RAS; it has been used more in the treatment of Behcet’s disease. 
Azathioprine 25mg/day was found to be an effective therapy in the management of oral and 
genital ulcerations, uveitis and arthritis in 73 patients with BD [73] and at 2.5mg/kg very 
effective in controlling uveitis [74]  
 
Thalidomide is an anti-TNF-a therapy which was first marketed as a sedative medication in 
1957. Afterwards, Thalidomide was used for the treatment of nausea and morning sickness in 
pregnant women but soon became infamous for its teratogenicity. This led to the 
establishment of more structured regulations and control over drug uses, particularly in 
females. It is recommended that use of Thalidomide should be accompanied by Nerve 
Conduction Studies (NCS) and Electromyography (EMG) every 6 months to rule out 
peripheral neuropathy.   
Nevertheless, thalidomide is considered to be an effective therapy for the managements of 
major RAS, and can be considered when other treatments have failed. Complete remission in 
85% -90% of patients with severe RAS has been reported using thalidomide 100mg a day for 
a range of periods from 3-6 months. [38,75].  Two open trials in patients with complex 
aphthosis (ie oral and genital ulceration not fulfilling the criteria for Behcets syndrome) 
showed that thalidomide could be very effective at doses from 50 to 150mg a day over 4 
years. Peripheral neuropathy was detected in some patients [76].  Remission in complex 
aphthosis without adverse events with low dose thalidomide (25mg/day) has also been 
reported [77]   
 
Levamisole. Used at a dose of 50mg daily has been shown to be effective in reducing ulcer 
duration, number and frequency of recurrences [90]. Some variation in studies and not all 
have found uniformly positive results. Most trials are short term and longer terms are needed 
[70, 71, 86, 90]. Some RAS actually get worse but few side effects have been reported [91]. 
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Dapsone has been reported to reduce ulcer recurrences in Complex aphthosis with a daily 
dose of 50 -125 mg [75, 76, 78]. The exact mechanism is thought to be due to its anti-
neutrophilic action. However, Dapsone should not be administered to patients with a glucose-
6-phosphate dehydrogenase (G6PD) deficiency and regular monitoring for haemolytic 
anaemia or methemaglobinaemias is essential 
 
Colchicine is an anti-inflammatory agent that limits leukocyte activity by binding to Beta-
Tubulin, a cellular microtubular protein, and therefore inhibiting protein polymerization [79]. 
Although Colchicine is generally well tolerated, the most frequent gastrointestinal adverse 
events include nausea, diarrhoea, vomiting, and abdominal pain.  Colchicine at 1.5mg/day 
over 3 months showed a significant improvement of ulcers in over two thirds of patients,[72, 
80, 81], but over 25% of patients reported side effects, mainly abdominal pain [80].  Similar 
results have been reported in other trials with 1.8mg/day showing effectiveness in complex 
aphthosis but a high rate of side effects [78]. Colchicine has been shown to be safe with a low 
dose of 0.5-1mg a day in children aged 3.5-11 years old with Periodic fever, Aphthous 
stomatitis, Pharyngitis and Adenitis disease (PFAPA) [82]. 
Lower doses (500ugm/day) appear effective when combined with topical steroids for 
3 months [51]. These findings suggested that in the short-term topical steroids improved ulcer 
symptoms, while Colchicine seemed to prevent recurrences. This study used an Ulcer 
Severity Score (USS) (see above).  A comparison of Prednisolone 5mg/day or Colchicine 
0.5mg/day for 3 months in a double-blind clinical trial of RAS showed effectiveness of both 
modalities of treatments. Adverse events were reported in Colchicine group (52.9%) 
compared to 11.8% in the Prednisolone group [68]. 
Other treatments of RAS 
The use of intra-lesional injections of steroids in severe cases of RAS with large single 
ulcers affecting quality of life such as eating, talking and swallowing, can be considered. 
Immediate relief of pain and a significant improvement in healing time with a single session 
of Carbon dioxide (CO2) laser treatment in patients with minor RAS has been reported in 
randomised controlled trials [83,84] More recently injection of Botulinum toxin has been 
reported as effective in relieving pain [85]. However, they are directed at healing current 
ulcers, and concurrent systemic treatment is usually needed for prevention of new ulcers 
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Table 3. Recommended treatments in three different types of RAS Effectiveness of 
treatment to be monitored in every patient by use of Ulcer Severity Score  [51] and OHIP 
quality of life score [52]. There is not as yet an evidence based consensus for protocols. 
 
 
 
 
  
 First line treatment 2nd line treatment maintenance treatment 
Minor RAS For three months Local 
steroid mouthwash four 
times a day when 
ulcers present,  twice 
daily when not. 
Colchicine 500-1000 
ugm/day for three to 
six months 
Local steroid 
mouthwash four times 
a day when ulcers 
present,  
Major RAS Colchicine 500-1000 
ugm/day for 6 months. 
Short course of 
systemic steroids may 
precede 
Azathioprine 50-100 
mg/day 
Local steroid 
mouthwash four times 
a day when ulcers 
present 
Herpetiform RAS Tetracycline 
mouthwashes four 
times a day when 
ulcers 
Colchicine 500-1000 
ugm/day for 3-6 
months 
Tetracycline 
mouthwashes four 
times a day in 
prodrome 
RAS in children Hydrocortisone 
hemisuccinate pellets 
2.5mg four times daily 
Local steroid 
mouthwash four times 
a day when ulcers 
present, 
Continue for 3 months, 
twice daily if no ulcers 
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Conclusions 
A variety of treatments for RAS abound in Oral Medicine, but even with what have become 
standard therapies such as local steroids, there are few clinical trials. The failure to 
standardize clinical diagnoses, and the failure to have robust clinical severity scores for RAS 
has lead to reporting a variety of clinical outcomes. The use of an ulcer severity score should 
allow both the severity of the entry of patients with RAS to be compared, but also the 
effectiveness of treatments to be followed on a routine basis. The recent report that an 
evidence based review of treatments was not possible because of the variety of outcomes 
used, emphasises the need for agreed outcome measures. 
A second issue in the literature is the failure to clearly distinguish between treatments 
designed to heal current ulcers and the much more difficult challenge of preventing new ulcer 
episodes. Almost any anti-bacterial agent, or anti-inflammatory agent can be expected to aid 
healing and pain, but few would be expected to prevent new ulcers episodes. Local steroid 
mouthwashes appear to be efficacious and the topical therapy of first choice, and there is 
evidence that local steroid mouthwashes can reduce the ulcer frequency as well as aid healing 
of current ulcers.  
Prevention of new ulcers normally requires systemic therapy. There was strong evidence in 
the majority of the studies that supported the efficacy and safety of Colchicine in the 
management of RAS in spite of a high proportion of gastric upsets at the doses used. 
However, the majority of the studies were for a short period (3-6 months) and there was a 
lack of a randomised clinical trial with a good sample size. Thalidomide demonstrated 
conclusive benefits with a dose of 50-150mg/day in the managements of Major RAS, but 
should not be a treatment of first choice. Azathioprine is relatively untried in Major RAS and 
would not seem to be the agent of first choice in minor RAS. Pentoxifylline and dapsone 
appear worthy of further trials for efficacy. A suggested protocol is seen in table 3. 
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